PVWM
BMY.RT

Point View Wealth Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Point View Wealth Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-11,761
Closed -$42K – 265
2020
Q2 		$42K Hold
11,761
– – 0.02% 254
2020
Q1 		$45K Hold
11,761
– – 0.02% 245
2019
Q4 		$35K Buy
+11,761
New +$30.6K 0.01% 277

Other funds holding BMY.RT

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Point View Wealth Management's BMY.RT Position: Q3 2020 in Review

Point View Wealth Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2020, closing a stake of 11,761 shares — an estimated $42K sold.

Point View Wealth Management first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $45K in Q1 2020. 571 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2020.

  • Point View Wealth Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2020 after selling out during the quarter.
  • Point View Wealth Management sold 11,761 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2020, an estimated $42K.
  • Point View Wealth Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • Point View Wealth Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $45K in Q1 2020.
  • 571 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2020.

Based on Point View Wealth Management's 13F filing for Q3 2020, filed 6 Nov 2020.